AstraZeneca rejects Pfizer's "final" bid

Share this article:

Managers from AstraZeneca rebuffed another offer to relinquish their autonomy, saying Pfizer's latest bid for the British drugmaker, a Friday night proposal valued at 69.4 billion pounds ($117 billion), was too low. The rejection of the bid, which Pfizer said was final, left the two drugmakers in a stalemate over a deal that would have created the world's largest drugmaker.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.